EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single‐arm FIL ‐ BRB trial

Giulia Benevolo iD, Daniela Drandi, Nicoletta Villivà, Anna Castiglione, Federico Monaco, Carola Boccomini iD, Daniela Dessi, Catello Califano, Luigi Curreli, Federica Cavallo iD, Annarita Conconi, Gianluca Gaidano und 13 weitere

British Journal of Haematology · 2025

DOI: 10.1111/bjh.19920 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Giulia Benevolo und 24 weiteren Autor:innen. Beteiligte Einrichtung: AOU Città della Salute e della Scienza di Torino-Ematologia U, Turin, Italy. Hauptthemen laut MEDLINE: Waldenstrom Macroglobulinemia, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This multicentre phase II study Fondazione Italiana Linfomi (FIL)‐bortezomib plus rituximab plus bendamustine (BRB) tested a combination of bendamustine (90 mg/m 2 on days 1–2), rituximab (375 mg/m 2 intravenously on day 1) and bortezomib (1.3 mg/m 2 sc on days 1, 8, 15, 22) every 28 days for six cycles in 38 symptomatic patients with relapsed/refractory Waldenstrom macroglobulinaemia (RR‐WM). Moreover, MYD88 L265P and CXCR4 S338X mutations were tested by droplet digital polymerase chain reaction (ddPCR) both at baseline and at the end of treatment in 21 patients. Overall response rate at the end of therapy was 84.6%, including 4 (11%) complete remission, 15 (39%) very good partial response, 12 (32%) partial responses according to IWWM response criteria. At 18, 24 and 30 months, progression‐free survival was 84.2% (95% CI 68.2%–92.6%), 81.5% (95%CI 65.1–90.7) and 78.8% (95%CI 62.0–88.8) respectively. At 18 months, the Overall survival was 92.1% (95%CI 77.5%–97.4%). Overall, 19 patients (50%) experienced grade 3–4 haematological toxicity, mainly thrombocytopenia, and grade 1–3 neuropathy rate was about 10% and required bortezomib dose reduction but did not result in treatment interruption. Moreover, BRB treatment induced the high rates of undetectable molecular minimal residual disease (MRD) at the end of the therapy. BRB regimen used as second line is an effective and well‐tolerated salvage treatment for relapsed refractory Waldenstrom macroglobulinaemia patients. MRD monitoring showed promising efficacy in clearing the residual disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Waldenstrom MacroglobulinemiaAntineoplastic Combined Chemotherapy ProtocolsHumansBendamustine HydrochlorideRituximabMaleFemaleAgedBortezomibMiddle AgedAdultRecurrenceAged, 80 and overTreatment OutcomeMyeloid Differentiation Factor 88

Stichwörter der Autor:innen

Waldenstrom‐S macroglobulinaemiachemotherapyimmunotherapymolecular biology

Substanzen

Bendamustine HydrochlorideRituximabBortezomibMYD88 protein, humanMyeloid Differentiation Factor 88

Autor:innen und Institutionen

  • AOU Città della Salute e della Scienza di Torino-Ematologia U, Turin, Italy.
  • Ematologia U, Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Università di Torino, Turin, Italy.
  • UOSD di Ematologia, ASL Roma 1, Rome, Italy.
  • SSD Epidemiologia Clinica e Valutativa-AOU Città della Salute e della Scienza di Torino e CPO, Piemonte, Italy.
  • AOSS Antonio e Biagio e Cesare Arrigo-SC Ematologia, Alessandria, Italy.
  • AOU Città della Salute e della Scienza di Torino-Ematologia, Turin, Italy.

ORCID-Profile: Giulia Benevolo, Carola Boccomini, Federica Cavallo, Michele Merli, Marzia Varettoni, Simone Ferrero

Zitieren

APA

Benevolo, G., Drandi, D., Villivà, N., Castiglione, A., Monaco, F., Boccomini, C., Dessi, D., Califano, C., Curreli, L., Cavallo, F., Conconi, A., Gaidano, G., Rossi, F. G., Caravita di Toritto, T., Ferrante, M., Mannina, D., Tosi, P., Pietrantuono, G., Musuraca, G., …, & Ferrero, S. (2025). Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single‐arm FIL ‐ BRB trial. British Journal of Haematology. https://doi.org/10.1111/bjh.19920

Vancouver

Benevolo G, Drandi D, Villivà N, Castiglione A, Monaco F, Boccomini C, et al. Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single‐arm FIL ‐ BRB trial. British Journal of Haematology. 2025. doi:10.1111/bjh.19920

BibTeX
@article{Benevolo2025,
  author = {Benevolo, Giulia and Drandi, Daniela and Villivà, Nicoletta and Castiglione, Anna and Monaco, Federico and Boccomini, Carola and Dessi, Daniela and Califano, Catello and Curreli, Luigi and Cavallo, Federica and Conconi, Annarita and Gaidano, Gianluca and Rossi, Francesca Gaia and Caravita di Toritto, Tommaso and Ferrante, Martina and Mannina, Donato and Tosi, Patrizia and Pietrantuono, Giuseppe and Musuraca, Gerardo and Merli, Michele and Sartori, Roberto and Tani, Monica and Freilone, Roberto and Varettoni, Marzia and Ferrero, Simone},
  title = {Efficacy and safety of bendamustine, rituximab and bortezomib treatment in relapsed/refractory Waldenstrom Macroglobulinaemia: results of phase 2 single‐arm FIL ‐ BRB trial},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.19920}
}
Kostenlos starten →